Haemonetics Corporation (HAE) |
48.85 -1.3 (-2.59%) 10-10 16:00 |
Open: | 50.26 |
High: | 50.27 |
Low: | 48.17 |
Volume: | 717,146 |
Market Cap: | 2,353(M) |
PE Ratio: | 14.94 |
Exchange: | New York Stock Exchange |
Industry: | Medical - Instruments & Supplies |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 54.52 |
Resistance 1: | 51.77 |
Pivot price: | 49.48 |
Support 1: | 47.32 |
Support 2: | 39.37 |
52w High: | 94.99 |
52w Low: | 47.32 |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
EPS | 3.270 |
Book Value | 18.320 |
PEG Ratio | 0.00 |
Gross Profit | 16.420 |
Profit Margin (%) | 12.14 |
Operating Margin (%) | 20.21 |
Return on Assets (ttm) | 6.5 |
Return on Equity (ttm) | 18.3 |
Fri, 10 Oct 2025
Haemonetics (HAE): Analyst Downgrades Spark New Discussion on Valuation and Future Growth Potential - simplywall.st
Thu, 09 Oct 2025
Haemonetics (NYSE:HAE) Receives Hold (C-) Rating from Weiss Ratings - MarketBeat
Tue, 07 Oct 2025
Citigroup Maintains Haemonetics (HAE) Buy Recommendation - Nasdaq
Tue, 07 Oct 2025
Citigroup Lowers Price Target for Haemonetics (HAE) to $64.00 | - GuruFocus
Mon, 06 Oct 2025
Hunter Perkins Capital Management LLC Acquires Shares of 7,100 Haemonetics Corporation $HAE - MarketBeat
Fri, 03 Oct 2025
Is Haemonetics (HAE) Undervalued? A Fresh Look at the Company’s Current Valuation - Sahm
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |